| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/01/2007 | WO2007012133A1 Therapeutic protocols using hyaluronan |
| 02/01/2007 | WO2006134160A3 Synergistic mixtures of aromatic alcohols and derivatives thereof and tropolone (derivatives) |
| 02/01/2007 | WO2006133654B1 USE OF NF-κB INHIBITOR FOR TREATING SEVERAL DISEASES |
| 02/01/2007 | WO2006133097A3 Use of alternating amine and non-amine bisphosphonate combinations for treating osteoporosis |
| 02/01/2007 | WO2006132811A3 Ampa receptor potentiators |
| 02/01/2007 | WO2006129120A3 Benzotriazepinone derivatives |
| 02/01/2007 | WO2006127932A3 Purification of cinacalcet |
| 02/01/2007 | WO2006127133A3 Compounds for the treatment of metabolic disorders |
| 02/01/2007 | WO2006122156A3 Compounds for modulating trpv3 function |
| 02/01/2007 | WO2006116630A3 Method for use of acetyl-l-carnitine ( alcar) for treatment of depressive disorders in humans |
| 02/01/2007 | WO2006116184A3 Methods and compositions for controlling invertebrate pests |
| 02/01/2007 | WO2006108689A3 Process for preparing bicyclic compounds |
| 02/01/2007 | WO2006105374A3 Optimizing pharmacodynamics of therapeutic agents for treating vascular tissue |
| 02/01/2007 | WO2006102604A8 Topical formulations of borinic acid antibodies and their methods of use |
| 02/01/2007 | WO2006097744A3 Phenol derivatives and their use to modulate pkb activity |
| 02/01/2007 | WO2006095363B1 Injectable preparations of diclofenic and its pharmaceutically acceptable salts |
| 02/01/2007 | WO2006091580A3 Hydrophobic starch compositions and uses of starch as fuel |
| 02/01/2007 | WO2006089221A3 Compounds inhibiting the aggregation of superoxide dismutase-1 |
| 02/01/2007 | WO2006088814A3 Dosage form and method for sustained release of a substituted pyrazine compound |
| 02/01/2007 | WO2006088473A3 Microcapsules and nanocapsules for the transmucosal delivery of therapeutic and diagnostic agents |
| 02/01/2007 | WO2006086609A3 Inhibitors of tryptase |
| 02/01/2007 | WO2006086255A3 Inhibitors of checkpoint kinases |
| 02/01/2007 | WO2006079057A3 Methods and compositions for specific inhibition of protein splicing by small molecules |
| 02/01/2007 | WO2006074919A3 3-AMINO-6-ARYL(OR 6-HETEROARYL)-THIENO[2,3-B]PYRIDIN-2-CARBOXAMIDES, PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME AND THEIR USE AS TNFα INHIBITORS |
| 02/01/2007 | WO2006073457A3 Bioactive compounds and methods of uses thereof |
| 02/01/2007 | WO2006065529A3 Compositions comprising polymeric emulsifiers and methods of using same |
| 02/01/2007 | WO2006060196A3 Use of rottlerin and its derivatives as activators of bk channel for therapy of hypertension and related disorders |
| 02/01/2007 | WO2006055854A3 Methods for reducing the side effects associated with mirtazapine treatment |
| 02/01/2007 | WO2006050162A3 Imidazole derivatives |
| 02/01/2007 | WO2006049734A3 Quetiapine analogs and methods of use thereof |
| 02/01/2007 | WO2006047755A3 Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (hit) syndrome |
| 02/01/2007 | WO2006045056A3 Flavonoid composition for treating oral diseases |
| 02/01/2007 | WO2006039656A3 Modified small interfering rna molecules and methods of use |
| 02/01/2007 | WO2006033891A3 Compounds for the treatment of dyslipidemia and other lipid disorders |
| 02/01/2007 | WO2006031806A3 2-thiopyrimidinones as therapeutic agents |
| 02/01/2007 | WO2006026095A3 Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid |
| 02/01/2007 | WO2006023848A3 Rna interference vectors |
| 02/01/2007 | WO2006023704A3 Lonidamine analogues and their use in male contraception and cancer treatment |
| 02/01/2007 | WO2006014930A3 Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation |
| 02/01/2007 | WO2006007411A3 Methods and compositions for modulating bax-mediated apoptosis |
| 02/01/2007 | WO2006007398A9 Therapy of platinum-resistant cancer |
| 02/01/2007 | WO2006002802A8 Phenyl derivatives comprising an acetylene group |
| 02/01/2007 | WO2005123055A3 Methods for treating inflammatory disorders |
| 02/01/2007 | WO2005112919A3 Self-immolative linkers and drug conjugates |
| 02/01/2007 | WO2005092065A3 Novel tricyclic compounds and related methods of treatment |
| 02/01/2007 | WO2005082049A3 Artificial biocompatible material as a support for cells in a retinal implant |
| 02/01/2007 | WO2005081816A3 Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants |
| 02/01/2007 | WO2005077082A3 INHIBITING CAV3 ISOFORMS AND THE δ25B SPLICE VARIENTS FOR THE DIAGNOSIS AND TREATMENT OF CANCER |
| 02/01/2007 | WO2005072462A3 Enhancement of anti-androgenic activity by a combination of inhibitors targeting different steps of a steroid-dependent gene activation pathway and uses thereof |
| 02/01/2007 | WO2005065551A3 Treatment of skin using a benefit agent and an apparatus |
| 02/01/2007 | WO2005063745A9 Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof |
| 02/01/2007 | WO2005026184A3 Synthesis and compositions of 2'-terminator nucleotides |
| 02/01/2007 | US20070028315 DNA encoding SNORF33 receptor |
| 02/01/2007 | US20070027330 One pot synthesis of taxane derivatives and their conversion to paclitaxel and docetaxel |
| 02/01/2007 | US20070027328 Processes for desolvating solvates of atorvastatin hemi-calcium and atorvastatin hem-calcium essentially free of organic solvent |
| 02/01/2007 | US20070027323 Crystal structure; hydrates; dissolving in solution; adding base; cooling; crystallization; salt formation |
| 02/01/2007 | US20070027322 N-substituted carbamoyloxyalkyl-azolium derivatives |
| 02/01/2007 | US20070027321 Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5 |
| 02/01/2007 | US20070027304 Mammalian IAP gene family, primers, probes and detection methods |
| 02/01/2007 | US20070027218 Pharmaceutical compositions comprising higher primary alcohols and ezetimibe and process of preparation thereof |
| 02/01/2007 | US20070027217 Composition and Method for Preventing Secondary Burn Ischemia |
| 02/01/2007 | US20070027216 Novel hydrochloride salts of levodopa |
| 02/01/2007 | US20070027215 Nuclear receptor ligands and ligand binding domains |
| 02/01/2007 | US20070027214 Orally administered agent for improving skin condition |
| 02/01/2007 | US20070027213 For therapy of depressive condition |
| 02/01/2007 | US20070027212 3-Aminomethyl-5-methyl-octanoic acid; antidepressant and anxiolytic agent; obsessive compulsive disorder (OCD), agoraphobia, agoraphobia without history of panic disorder, specific phobia, social phobia, restless legs syndrome, premenstrual dysphoric disorder, hot flashes, and fibromyalgia; not addictive |
| 02/01/2007 | US20070027211 Process for production of bicalutamide |
| 02/01/2007 | US20070027210 trans-4-{[(2-methylpropanoyloxy)methoxycarbonyl]aminomethyl}-cyclohexanecarboxylic acid; reversibly blocks lysine binding sites on plasminogen and plasmin; stabilize fibrin clots, control excess bleeding; oral bioavailability |
| 02/01/2007 | US20070027209 Prevention and treatment of atherosclerosis with lithospermate B |
| 02/01/2007 | US20070027208 Antiparkinsonian Action of Phenylisopropylamines |
| 02/01/2007 | US20070027207 Semi-synthesis of taxane intermediates and their conversion to paclitaxel and docetaxel |
| 02/01/2007 | US20070027206 Iminocarboxylic acid salt-containing solid composition and production method thereof |
| 02/01/2007 | US20070027205 Diarylmethyl derivatives as potassium channel modulators |
| 02/01/2007 | US20070027204 anxiety, depression, epilepsy, schizophrenia, and cognitive disorders; gamma -Aminobutyric acid receptors modulators; 5,7-Di-tert-butyl-3-hydroxy-3-trifluoromethyl-1,3-dihydro-indol-2-one |
| 02/01/2007 | US20070027203 Method of treating inflammatory arthritis |
| 02/01/2007 | US20070027202 Process for the preparation of carvedilol and its salts |
| 02/01/2007 | US20070027201 Use of progesterone receptor modulators |
| 02/01/2007 | US20070027200 Bis-benzimidazoles and related compounds as potassium channel modulators |
| 02/01/2007 | US20070027199 Cycloalkyl amino-hydantoin compounds and use thereof for beta-secretase modulation |
| 02/01/2007 | US20070027198 Crystal of heterocyclic compound |
| 02/01/2007 | US20070027197 Pharmaceutical composition and method for the treatment of diseases using HMG-CoA reductase inhibitors and insulin secretion enhancers or sensitizers |
| 02/01/2007 | US20070027196 Activator of peroxisome proliferator-activated receptor delta |
| 02/01/2007 | US20070027195 Novel compositions comprising higher primary alcohols and nicottinic acid and process of preparation thereof |
| 02/01/2007 | US20070027194 Treatment of actinic keratoses with calcium channel blockers |
| 02/01/2007 | US20070027193 Compounds capable of binding to the ubiquinone binding site of dihydroorotate dehydrogenase containing a non-aromatic ring system as a core structure and a group capable of interacting with various elements of ubiquinone binding sites of DHODH |
| 02/01/2007 | US20070027192 N-{[1-(Methylamino)cyclopropyl]methyl}pyridin-3-amine dihydrochloride; treatment of neuropathologies associated with cerebral ageing, of mood disorders, of pain and of tobacco withdrawal; selective nicotinic ligands of the central receptor sub-type alpha 4 beta 2 |
| 02/01/2007 | US20070027191 N,2-dimethyl-1-[(3-pyridinyloxy)methyl]cyclopropanamine; nicotinic receptors of type alpha 4 beta 2 ligand; neurodegenerative diseases: Alzheimer's, Parkinson's, Pick's, attention-deficit hyperactivity syndrome |
| 02/01/2007 | US20070027190 Antibacterial fab i inhibitors |
| 02/01/2007 | US20070027189 Use of known active ingredients as radical scavengers |
| 02/01/2007 | US20070027188 di-tert-butyl 4-{[1-(3,3-dimethyl-2-oxobutyl)-6-methoxy-1-H-indazole-3-yl]carbonyl}benzylphosphate; potassium channel blocker; eye neuroprotectant; hypotensive agent; glaucoma, elevated intraoccular pressure in the eye |
| 02/01/2007 | US20070027187 Vanilloid receptor (VR1) antagonists; side effects reduction, oral availability; To treat urinary incontinence, urge urinary incontinence, overactive bladder, pain, and/or inflammatory diseases such as asthma and COPD; N-[2-(2-Fluorophenoxy)ethyl]-N'-(7-hydroxy-5,6,7,8-tetrahydro-1-naphthalenyl)-urea |
| 02/01/2007 | US20070027186 Synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones |
| 02/01/2007 | US20070027185 inhibitor of factor Xa and/or thrombin; anticoagulantsto treat thromboembolic disorders, myocardial ischemia, myocardial infarction and cerebral thrombosis; N-(5-chloropyridin-2-yl)-3-[2-(piperidin-4-yloxy)-4-(pyrrolidin-1-yl)benzoylamino]pyridine-4-carboxamide; high bioavailability; acylation |
| 02/01/2007 | US20070027184 Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease |
| 02/01/2007 | US20070027183 Inhibitors of microsomal triglyceride transfer protein and apo-B secretion |
| 02/01/2007 | US20070027182 e.g. N-(4a-(3-Methoxyphenyl)-8a-methyl-2-(3-phenylpropyl)octahydroisoquinolin-6-yl]-3-piperidin-1-yl-propionamide; opioid receptor antagonist; analgesic, antidepressant; nervous system disorder; drug abuse, obesity |
| 02/01/2007 | US20070027181 Benzylisoquinoline derivative- or bisbenzylisoquinoline derivative-containing psychotropic agent, analgesic and/or antiphlogistic, and health food |
| 02/01/2007 | US20070027180 Process for preparing zolpidem |
| 02/01/2007 | US20070027179 Azaindole derivatives, preparations thereof, uses thereof and compositions containing them |
| 02/01/2007 | US20070027178 Substituted tetrahydro-1H-pyrido[4,3-b]indoles as serotonin receptors agonists and antagonists |